The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Updates on the FLT3 inhibitor FF-10101 for the treatment of R/R AML
Mark Levis, MD, PhD, John Hopkins University, Baltimore, MD, highlights the benefits of the irreversible FLT3 inhibitor FF-10101 for the treatment of refractory/relapsed acute myeloid leukemia (R/R AML), including its short half-life and dosage. Dr Levis expresses disappointment over its halt in development but mentions a similar drug that has demonstrated promising potential. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
